{
  "id": 18272889,
  "title": "Carlsmed COO Jeffrey Bertolini sells $11,317 in company stock",
  "url": "https://urgent.news/2026/11/05/carlsmed-coo-jeffrey-bertolini-sells-11-317-in-company-stock",
  "topic": "business",
  "section": "Business",
  "published": "2026-11-05T08:01:06.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/carlsmed-coo-jeffrey-bertolini-sells-11317-in-company-stock-93CH-5002473"
  },
  "original_language": "en",
  "account": "Jeffrey Bertolini, the COO of Carlsmed Inc., sold 747 shares of the company's stock on November 3, 2026, for a total of $11,317. This sale occurred on the same day he bought an equal number of shares through the exercise of stock options. The shares were sold at $15.15 each, under a pre-approved trading plan established by Mr. Bertolini on March 12, 2026. The sale comes as Carlsmed's shares are trading close to their 52-week high of $17.23, currently priced at $16.09. Despite being overvalued according to InvestingPro analysis, the stock has still delivered an 80% return over the last six months.\n\nPrior to the sale, Mr. Bertolini purchased 747 shares for $4,418 by exercising stock options at $5.915 per share on the same date. After these transactions, he now directly owns 22,489 shares of Carlsmed common stock, in addition to holding 20,908 stock options, with 25% of which vested on March 3, 2026, and the remaining 75% set to vest in monthly installments over the next year, contingent on his continued service. This information was documented and signed by Michael Cordonnier, acting as attorney-in-fact for Mr. Bertolini, on November 4, 2026.\n\nIn related news, Carlsmed reported a 57% increase in second-quarter revenue to $18.9 million, boosted by a surge in procedure volume. The company also expanded its gross margin and has revised its full-year revenue outlook upwards, indicating robust demand for its personalized spine surgery platform. Truist Securities responded positively to these results by raising their price target for Carlsmed from $18 to $20, maintaining a Buy rating. They cited the company's strong second-quarter performance and increased full-year outlook as the reasons behind their decision. Furthermore, Carlsmed experienced a more than 60% growth in trained surgeons during the quarter, adding to their growth prospects. These developments emphasize Carlsmed's solid performance and optimistic future outlook as perceived by Truist.",
  "summary": null,
  "key_points": [
    "COO Jeffrey Bertolini sold 747 shares of Carlsmed stock for $11,317 on November 3, 2026.",
    "Shares were sold at $15.15 each, under a pre-approved trading plan from March 12, 2026.",
    "Carlsmed shares are trading near their 52-week high of $17.23, currently at $16.09."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}